At one stage in the early flurry of dealings the market cap had soared to $98.9 million.
The stock debuted at 226p but peaked at 250p at the height of activity: As exclusively predicted in Business Weekly mid-May, the UK business raised £20 million in an oversubscribed round.
Arecor is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products.